{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:11:54Z","timestamp":1786547514184,"version":"build-2736575974"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study aims to explore the research hotspots and trends of multiple myeloma bone disease in the past 20\u00a0years by bibliometric visualization analysis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> With the Web of Science Core Collection database as the data source, the relevant publications of multiple myeloma bone disease from 2002 to 2021 are retrieved. These data are analyzed using software CiteSpace 5.8.R3 and Scimago Graphica 1.0.24, together with the Online Analysis Platform of Literature Metrology.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 6,168 published research papers, including 4668 articles and 1500 review papers, are included in this study. Generally speaking, annual publications and citations are on the rise, especially in recent 2\u00a0years. The majority of these papers are published in the United States, with Mayo Clinic being the greatest contributor. The most productive journal and author are <jats:italic>Blood<\/jats:italic> and Terpos E, respectively, while the most frequently co-cited reference, author and journal are Rajkumar et al., 2014, <jats:italic>Lancet Oncol<\/jats:italic>, Kyle RA and <jats:italic>Blood<\/jats:italic>, respectively. The major research subject categories are oncology and hematology. The \u201cdisease diagnosis\u201d, \u201cprognosis evaluation\u201d, \u201cpathogenesis\u201d, \u201cimaging technology\u201d and \u201ctargeted therapy\u201d are recent research frontiers. The burst keywords \u201ctransplantation\u201d, \u201cprogression\u201d, \u201cactivation\u201d, \u201clenalidomide\u201d, \u201cflow cytometry\u201d, \u201cdrug resistance\u201d, \u201cmanagement\u201d and \u201cmesenchymal stem cell\u201d reflect the latest research hotspots.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study reveals the research hotspots and trends of multiple myeloma bone disease through bibliometric visualization analysis, and provides a valuable reference for further research.<\/jats:p>","DOI":"10.3389\/fphar.2022.1003228","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:38:24Z","timestamp":1665729504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhaomeng","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"775329","DOI":"10.3389\/fcvm.2022.775329","article-title":"Atrial fibrillation and depression: A bibliometric analysis from 2001 to 2021","volume":"9","author":"Ai","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"801851","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: Minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2022","journal-title":"Front. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fphar.2019.00246","article-title":"Trends and development in enteral nutrition application for ventilator associated pneumonia: A scientometric research study (1996-2018)","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"133932","DOI":"10.1016\/j.chemosphere.2022.133932","article-title":"Wastewater treatment and emerging contaminants: Bibliometric analysis","volume":"297","author":"Chen","year":"2022","journal-title":"Chemosphere"},{"key":"B7","doi-asserted-by":"publisher","first-page":"918483","DOI":"10.3389\/fpubh.2022.918483","article-title":"Mapping knowledge landscapes and emerging trends of the links between bone metabolism and diabetes mellitus: A bibliometric analysis from 2000 to 2021","volume":"10","author":"Cheng","year":"2022","journal-title":"Front. Public Health"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"690392","DOI":"10.3389\/fphar.2021.690392","article-title":"Bibliometric and visual analysis of vascular calcification research","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"941437","DOI":"10.3389\/fonc.2022.941437","article-title":"Molecular impact of the tumor microenvironment on multiple myeloma dissemination and extramedullary disease","volume":"12","author":"Forster","year":"2022","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1245\/s10434-020-08819-6","article-title":"Orthopedic surgical treatment and perioperative complications in multiple myeloma bone disease: Analysis of a series (2009-2018)","volume":"28","author":"Gal\u00e1n-Olleros","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"689553","DOI":"10.3389\/fonc.2021.689553","article-title":"Mapping intellectual structures and research hotspots of triple negative breast cancer: A bibliometric analysis","volume":"11","author":"Hao","year":"2021","journal-title":"Front. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"725162","DOI":"10.3389\/fphar.2021.725162","article-title":"Scientometric analysis of medicinal and edible plant coptis","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med. J. Aust."},{"key":"B17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3389\/fphar.2020.00842","article-title":"Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010-2019)","volume":"11","author":"Ke","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the international myeloma working group","volume":"121","author":"Kyle","year":"2003","journal-title":"Br. J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1108\/IJICC-06-2020-0067","article-title":"Bibliometric analysis on Pythagorean fuzzy sets during 2013-2020","volume":"14","author":"Lin","year":"","journal-title":"Int. J. Intell. Comput. Cybern."},{"key":"B23","doi-asserted-by":"publisher","first-page":"771810","DOI":"10.3389\/fgene.2021.771810","article-title":"Mapping intellectual structure for the long non-coding RNA in hepatocellular carcinoma development research","volume":"12","author":"Lin","year":"","journal-title":"Front. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"772386","DOI":"10.3389\/fphar.2021.772386","article-title":"Knowledge domain and emerging trends in podocyte injury research from 1994 to 2021: A bibliometric and visualized analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fphar.2020.00294","article-title":"Knowledge mapping of angelica sinensis (oliv.) diels (danggui) research: A scientometric study","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"624534","DOI":"10.3389\/fphar.2021.624534","article-title":"Current status and trends in peptide receptor radionuclide therapy in the past 20 Years (2000-2019): A bibliometric study","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1108\/IJICC-02-2021-0034","article-title":"Flash translation layer: A review and bibliometric analysis","volume":"14","author":"Luo","year":"2021","journal-title":"Int. J. Intell. Comput. Cybern."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1158\/1535-7163.MCT-19-1020","article-title":"A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myeloma","volume":"19","author":"Marina","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-020-6596-y","article-title":"Bone complications in patients with multiple myeloma in five European countries: A retrospective patient chart review","volume":"20","author":"Mateos","year":"2020","journal-title":"BMC Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"840956","DOI":"10.3389\/fimmu.2022.840956","article-title":"A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.3390\/ijms22126208","article-title":"Myeloma bone disease: A comprehensive review","volume":"22","author":"Mukkamalla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s12325-021-02022-z","article-title":"Management of patients with relapsed and\/or refractory multiple myeloma treated with novel combination therapies in routine clinical practice in Germany","volume":"39","author":"Steinmetz","year":"2022","journal-title":"Adv. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: From bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3390\/cancers14112768","article-title":"Daratumumab improves bone turnover in relapsed\/refractory multiple myeloma; phase 2 study \u201cREBUILD","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.31128\/AJGP-01-18-4473","article-title":"Multiple myeloma: Updated approach to management in 2018","volume":"47","author":"Tomlinson","year":"2018","journal-title":"Aust. J. Gen. Pract."},{"key":"B47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/jbmr.4404","article-title":"A functional three-dimensional microphysiological human model of myeloma bone disease","volume":"36","author":"Visconti","year":"2021","journal-title":"J. Bone Min. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.3390\/ijms22115707","article-title":"Bruton\u2019s tyrosine kinase targeting in multiple myeloma","volume":"22","author":"Von Suskil","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: A national population-based analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"899235","DOI":"10.3389\/fcvm.2022.899235","article-title":"The application of angiotensin receptor neprilysin inhibitor in cardiovascular diseases: A bibliometric review from 2000 to 2022","volume":"9","author":"Xu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00108-018-0530-2","article-title":"Management of osseous complications in multiple myeloma","volume":"60","author":"Zarghooni","year":"2019","journal-title":"Internist (Berl)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"842919","DOI":"10.3389\/fmed.2022.842919","article-title":"Exercise-based renal rehabilitation: A bibliometric analysis from 1969 to 2021","volume":"9","author":"Zhang","year":"","journal-title":"Front. Med."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1108\/IJICC-01-2022-0004","article-title":"A comprehensive bibliometric analysis of Apache Hadoop from 2008 to 2020","author":"Zhang","year":"2022","journal-title":"Int. J. Intell. Comput. Cybern"},{"key":"B57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13018-022-02913-z","article-title":"Treatment of anterior shoulder instability: A bibliometric analysis","volume":"17","author":"Zhang","year":"","journal-title":"J. Orthop. Surg. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"843395","DOI":"10.3389\/fmed.2022.843395","article-title":"A bibliometric analysis of atrophic gastritis from 2011 to 2021","volume":"9","author":"Zhang","year":"","journal-title":"Front. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"851923","DOI":"10.3389\/fsurg.2022.851923","article-title":"Developments and emerging trends in the global treatment of chronic rhinosinusitis from 2001 to 2020: A systematic bibliometric analysis","volume":"9","author":"Zhou","year":"2022","journal-title":"Front. Surg."},{"key":"B60","doi-asserted-by":"publisher","first-page":"793347","DOI":"10.3389\/fcell.2021.793347","article-title":"Bibliometric evaluation of 2012-2020 publications on ferroptosis in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"894006","DOI":"10.3389\/fneur.2022.894006","article-title":"Global trends and hotspots in trigeminal neuralgia research from 2001 to 2021: A bibliometric analysis","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"687757","DOI":"10.3389\/fphar.2021.687757","article-title":"Comprehensive bibliometric analysis of the kynurenine pathway in mood disorders: Focus on gut microbiota research","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1003228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:38:28Z","timestamp":1665729508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1003228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":72,"alternative-id":["10.3389\/fphar.2022.1003228"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1003228","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"1003228"}}